Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Molecular cancer therapeutics - 1 Dec 2013

Ganesan Prasanth, Janku Filip, Naing Aung, Hong David S, Tsimberidou Apostolia M, Falchook Gerald S, Wheler Jennifer J, Piha-Paul Sarina A, Fu Siqing, Stepanek Vanda M, Lee J Jack, Luthra Rajyalakshmi, Overman Michael J, Kopetz E Scott, Wolff Robert A, Kurzrock Razelle

Abstract excerpt

Target-matched treatment with PI3K/AKT/mTOR pathway inhibitors in patients with diverse advanced cancers with PIK3CA mutations have shown promise. Tumors from patients with colorectal cancer were analyzed for PIK3CA, KRAS, and BRAF mutations. PIK3CA-mutated tumors were treated, whenever feasible,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24092809
DOI: 10.1158/1535-7163.MCT-13-0319-T
PMCID: PMC4158732

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24092809-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.PMID 24092809Read ↗

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.Semantic proximity Read ↗

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.Semantic proximity Read ↗

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.Semantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Semantic proximity Read ↗

PIK3CA mutations in advanced cancers: characteristics and outcomes.Semantic proximity Read ↗

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Semantic proximity Read ↗

Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Semantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract CancerSemantic proximity Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.